Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT

Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03589196

Acronym

EPPROSTATECT

Enrollment

Registered

2018-07-17

Start date

2018-03-10

Completion date

2019-12-01

Last updated

2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH With Urinary Obstruction, Ejaculation Abnormal, Prostate Disease, Prostate Obstruction, Prostatic Hyperplasia

Brief summary

To Evaluate and compare the outcome and coast of ejaculation sparing management of BPH using 3 different techniques: PVP, PKVP and TURP. Ejaculation sparing TURP group is considered the standard control group. Evaluation will be carried out through a prospective randomized powered trial

Interventions

PROCEDUREEjaculation Preserving Photoselective Vaporization

Ejaculation Preserving Photoselective Vaporization

PROCEDUREEjaculation Preserving Plasma Kinetic Vaporization

Ejaculation Preserving Plasma Kinetic Vaporization

PROCEDUREEjaculation Preserving Transurethral Resection Of The Prostate

Ejaculation Preserving Transurethral Resection Of The Prostate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 1\. Age \>50 years 2. Prostate volume (measured by TRUS): 30-80 gm 3. International prostate symptom score (IPSS )\>15 and quality of life score (QOL)\< 3. 4\. Maximum flow rate of uroflometry \<10 ml/second 5. Patients with active sexual life (or interested) and having the ability to ejaculate and desire to preserve ejaculation. 6\. Failure or intolerance to medical treatment, recurrent urinary infection, urine retention, significant hematuria or deterioration of the upper urinary tract function secondary to BOO.

Exclusion criteria

1. Bleeding disorders and patients on anticoagulant treatment 2. Histologically proved cancer prostate 3. Neurogenic voiding dysfunction 4. Lower urinary tract malignancy 5. Preoperative ejaculation or sexual dysfunction 6. Presence of stricture urethra 7. Unfit for spinal anathesia -

Design outcomes

Primary

Measure	Time frame	Description
estimate and compare the ejaculation preservation effect of the 3 techniques (PKVP, PVP and TURP).	1 years	assessed by Male Sexual Health Questionnaire (MSHQ)

Secondary

Measure	Time frame	Description
change in flow rate	1 years	measured by uroflowmetery in ml/sec
postoperative complication	1 year	measured by Clavien-Dindo Classification scale
change in patients' symptoms.	1 year	measured by International Prostate Symptom Score (I-PSS)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026